This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Culine, S. Articles by Fizazi, K. Search for Related Content PubMed PubMed Citation Articles by Culine, S. Articles by Fizazi, K. Social Bookmarking                            What's this?

Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site

From the Centre Régional de Lutte Contre le Cancer Val d’Aurelle, Montpellier; Institut Gustave Roussy, Villejuif; Institut Claudius Régaud, Toulouse; Centre Eugène Marquis, Rennes; Centre Paul Papin, Angers; and Centre Hospitalier Universitaire, Saint Etienne, France.

Address reprint requests to Stéphane Culine, MD, PhD, Department of Medicine, Centre Régional de Lutte Contre le Cancer Val d’Aurelle, 34298 Montpellier Cedex 5, France; email: stculine{at}valdorel.fnclcc.fr

PURPOSE: To identify clinical and biologic variables with significant impact on survival in patients with carcinomas of an unknown primary site and to develop a simple prognostic model for the selection of patients in prospective clinical trials.

PATIENTS AND METHODS: Univariate and multivariate prognostic factor analyses were conducted in a population of 150 unselected patients and led to the construction of two successive classification schemes. An external data set of 116 patients enrolled onto two prospective trials was used for validation.

RESULTS: When studying clinical variables only, poor performance status (2 or 3) and presence of liver metastases were retained in the multivariate analysis. The first classification scheme consisted of three subgroups of patients with median survivals of 10.8, 6.0, and 2.4 months, according to the number of adverse prognostic factors. With the introduction of serum lactate dehydrogenase (LDH) levels in a further step, liver metastases were no longer significant. The second classification scheme therefore included poor performance status (relative risk [RR], 2.1) and elevated serum LDH level (RR, 2.1). Good-risk and poor-risk patients were identified, with median survivals of 11.7 months and 3.9 months, respectively (P < .0001). The 1-year survival rates were 45% and 11%, respectively. This second classification scheme was validated in an external data set: the median survival rates of patients assigned to the good-risk group and the poor-risk group were 12 months and 7 months, respectively (P = .0089). The 1-year survival rates were 53% and 23%, respectively.

CONCLUSION: A simple prognostic model using performance status and serum LDH levels was developed and validated. It allows the assignment of patients into two subgroups with divergent outcome. Further prospective trials will be designed using this prognostic model.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Briasoulis, N. Pavlidis, E. Felip, and On behalf of the ESMO Guidelines Working Group Cancers of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv154 - iv155. [Full Text] [PDF]

				L. Boyland and C. Davis Patients' experiences of carcinoma of unknown primary site: dealing with uncertainty Palliative Medicine, March 1, 2008; 22(2): 177 - 183. [Abstract] [PDF]

				J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752. [Abstract] [Full Text] [PDF]

				S. S. Nathan, J. H. Healey, D. Mellano, B. Hoang, I. Lewis, C. D. Morris, E. A. Athanasian, and P. J. Boland Survival in Patients Operated on for Pathologic Fracture: Implications for End-of-Life Orthopedic Care J. Clin. Oncol., September 1, 2005; 23(25): 6072 - 6082. [Abstract] [Full Text] [PDF]

				A. Gutzeit, G. Antoch, H. Kuhl, T. Egelhof, M. Fischer, E. Hauth, S. Goehde, A. Bockisch, J. Debatin, and L. Freudenberg Unknown Primary Tumors: Detection with Dual-Modality PET/CT--Initial Experience Radiology, January 1, 2005; 234(1): 227 - 234. [Abstract] [Full Text] [PDF]

				S. Culine, A. Lortholary, J.-J. Voigt, R. Bugat, C. Theodore, F. Priou, M.-C. Kaminsky, T. Lesimple, X. Pivot, B. Coudert, et al. Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study--Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) J. Clin. Oncol., September 15, 2003; 21(18): 3479 - 3482. [Abstract] [Full Text] [PDF]